Herbst R.S. et al. retrospectively investigated the association between tissue TMB (tTMB) and the clinical benefit with pembrolizumab monotherapy observed in previously treated (KEYNOTE-010, NCT01905657) or treatment naïve (KEYNOTE-042, NCT02220894) PD-L1+ NSCLC patients. This evidence concerns the gene CD274 and non-small cell lung carcinoma.